Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Short Interest Down 35.2% in January

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) was the target of a significant drop in short interest in January. As of January 15th, there was short interest totalling 23,700 shares, a drop of 35.2% from the December 31st total of 36,600 shares. Approximately 0.7% of the company’s stock are sold short. Based on an average daily volume of 43,400 shares, the short-interest ratio is currently 0.5 days.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of LSB. Barclays PLC purchased a new stake in Lakeshore Biopharma in the 3rd quarter worth $169,000. FMR LLC purchased a new stake in shares of Lakeshore Biopharma in the 3rd quarter worth approximately $803,000. Finally, Hhlr Advisors LTD. purchased a new stake in shares of Lakeshore Biopharma in the 3rd quarter worth approximately $513,000. Hedge funds and other institutional investors own 52.64% of the company’s stock.

Lakeshore Biopharma Stock Performance

Shares of LSB opened at $2.72 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.17 and a quick ratio of 0.90. The firm has a 50 day moving average of $2.87 and a 200 day moving average of $3.91. Lakeshore Biopharma has a twelve month low of $1.88 and a twelve month high of $11.20.

Lakeshore Biopharma Company Profile

LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.